Does chronic GLP-1 receptor agonist exposure remodel the pancreas? What the evidence actually shows

Evidence review draft for UK healthcare professionals. This article summarises published research and current UK safety information; it does not replace product information, NICE guidance or individual prescribing judgement.

The short answer is that sustained GLP-1 receptor activation changes gene expression in experimental pancreatic models. The strongest evidence is in beta-cell lines and rodent islets. That is biologically interesting, but it is not the same as demonstrating that GLP-1 receptor agonists remodel the human pancreas during routine treatment.

For primary care, the practical message is more straightforward. The mechanistic research does not change who should be offered treatment. Current safety practice should continue to follow the product information and the MHRA’s January 2026 advice on acute pancreatitis.

What you need to know in 60 seconds

• Prolonged GLP-1 receptor stimulation produces sustained transcriptional and metabolic responses in beta-cell models.

• Rodent and cell studies report cell-type-specific effects in beta, alpha and exocrine pancreatic compartments.

• These studies do not establish that the same tissue-level changes occur in people taking GLP-1 receptor agonists.

• Acute pancreatitis is a recognised adverse effect. The MHRA’s current advice is to discontinue treatment immediately if pancreatitis is suspected and not restart it if confirmed.

The key distinction: mechanism is not clinical outcome

GLP-1 receptor agonists have immediate effects on glucose-dependent insulin secretion. A separate body of work asks what happens after more sustained receptor stimulation. In experimental systems, the answer is not simply a longer version of the acute response. Cells can show changes in transcriptional programmes, cellular metabolism and survival pathways.

The important qualifier is the model. Most of the direct mechanistic work has used rodent beta-cell lines, mouse or rat islets, or animal models of diabetes. These experiments can identify plausible biological pathways, but they cannot by themselves determine pancreatic safety, cancer risk or long-term tissue effects in people.

What beta-cell studies show

In a 2017 study, 18 hours of exendin-4 exposure increased glycolytic enzyme expression, glucose uptake, ATP content and insulin secretion in a rat beta-cell line and rodent islets. The reported effects depended on PI3K/mTOR signalling and HIF-1alpha activity. ¹

A newer mechanistic study, published in PNAS in March 2026, provides a more detailed example. In rat INS-1 beta cells, one hour of exendin-4 exposure altered 184 genes, whereas 16 hours altered 1,065. The sustained response included genes involved in metabolism, protein processing and cholesterol biosynthesis. The investigators identified phosphorylation of the transcriptional-complex component Med14 as necessary for part of this prolonged response; related experiments were undertaken in primary mouse islets. ²

What that means: prolonged receptor stimulation can drive a sustained beta-cell transcriptional programme in experimental models. It does not mean that treatment has been shown to permanently reprogramme the human pancreas.

Other preclinical work supports a beta-cell-protective pattern in diabetic rodent models. For example, 17 weeks of dulaglutide treatment in db/db mice was associated with improved beta-cell gene expression and lower markers of oxidative stress, endoplasmic-reticulum stress, inflammation, fibrosis and apoptosis. ³ These findings are hypothesis-generating for human biology, not evidence of an established long-term human tissue effect.

Alpha cells and the limits of regeneration claims

Alpha-cell findings should be treated even more cautiously. A mouse-derived alpha-cell-line study found increased GLP-1 synthesis and release after 72 hours of GLP-1 exposure. ⁴ Separate rodent studies reported alpha-to-beta-cell transdifferentiation after GLP-1 treatment. ^5,6

These studies are sometimes cited in discussions of beta-cell regeneration. They should not be translated into a claim that GLP-1 receptor agonists regenerate beta cells in adult humans. The relevant human pancreatic-tissue evidence is not available from these experiments.

Why exocrine-pancreas studies need context

The patient-facing safety questions are often about pancreatitis and pancreatic cancer. These concern the exocrine pancreas, which is biologically distinct from the islets.

Animal and cell studies have reported mixed exocrine findings. In mice, GLP-1 receptor activation changed expression of pancreatitis-associated genes without increasing susceptibility to experimental pancreatitis. ⁷ A 2012 study reported pancreatic duct-gland expansion in rats and acceleration of dysplastic pancreatic lesions in genetically predisposed KrasG12D mice treated with exendin-4. ⁸ In isolated rat pancreatic stellate cells, GLP-1 receptor activation increased proliferation without an accompanying increase in inflammatory-mediator expression. ⁹

These observations deserve accurate reporting, but they do not establish a human clinical causal pathway. They arise from selected preclinical models, including genetically predisposed animals, and cannot be used to infer that GLP-1 receptor agonists cause pancreatic cancer in people.

Clinical trial evidence has been broadly reassuring for pancreatic cancer, while remaining limited by rare events and follow-up time. A 2021 meta-analysis of eight cardiovascular outcome trials found no increased pancreatic-cancer signal with GLP-1 receptor agonists. ¹⁰ A separate randomised-trial meta-analysis likewise did not find an association, although its authors emphasised that longer follow-up would be needed to exclude smaller or later risks. ¹¹

What has changed for UK primary care: pancreatitis advice

The current actionable update is the MHRA Drug Safety Update of 29 January 2026. It states that acute pancreatitis is a recognised adverse effect of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. UK product information has been strengthened to highlight rare reports of necrotising and fatal pancreatitis. ¹²

The MHRA advises clinicians to remain alert to severe, persistent abdominal pain, particularly if it radiates to the back and is accompanied by nausea or vomiting. If pancreatitis is suspected, the GLP-1 or GLP-1/GIP receptor agonist should be discontinued immediately; treatment should not be restarted if pancreatitis is confirmed. The MHRA also advises caution in people with a history of pancreatitis and notes that privately supplied medicines may not appear in the routine medication record. ¹²

This is a safety message about recognised adverse effects and clinical assessment. It is not a conclusion drawn from the animal gene-expression studies.

How to answer the question in consultation

1. Experimental studies do show that GLP-1 receptor stimulation changes gene activity and cell behaviour in rodent pancreatic models, especially in insulin-producing beta cells.

2. Those mechanisms have not been demonstrated as the same long-term tissue effect in humans. Animal findings in the exocrine pancreas are mixed and do not prove a pancreatic-cancer risk in people.

3. The established clinical safety point is pancreatitis. Patients should know the symptoms that need urgent assessment, and clinicians should follow current product information and MHRA advice.

Bottom line

Chronic GLP-1 receptor agonist exposure produces sustained molecular responses in experimental pancreatic systems. The most persuasive evidence concerns beta-cell transcription and metabolism in rodent cells and islets. Exocrine findings are more heterogeneous and cannot determine human cancer risk.

For clinical practice, the evidence does not create a new indication, monitoring programme or patient-selection rule. It reinforces the need to keep mechanistic findings separate from clinical outcomes, while applying the current MHRA pancreatitis advice consistently.

References

1. Carlessi R, Chen Y, Rowlands J, et al. GLP-1 receptor signalling promotes beta-cell glucose metabolism via mTOR-dependent HIF-1alpha activation. Scientific Reports. 2017;7:2661. https://doi.org/10.1038/s41598-017-02838-2

2. Van de Velde S, Yu J, Evensen KG, et al. Med14 phosphorylation shapes genomic response to GLP-1 agonists. Proceedings of the National Academy of Sciences. 2026;123(10):e2536772123. https://doi.org/10.1073/pnas.2536772123

3. Kimura T, Obata A, Shimoda M, et al. Durability of protective effect of dulaglutide on pancreatic beta-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure. Diabetes & Metabolism. 2018;44(3):250–260. https://doi.org/10.1016/j.diabet.2017.10.007

4. Piro S, Mascali LG, Urbano F, et al. Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line. PLoS One. 2014;9(2):e90093. https://doi.org/10.1371/journal.pone.0090093

5. Lee YS, Lee CE, Choung J, et al. GLP-1 increases beta-cell regeneration by promoting alpha- to beta-cell transdifferentiation. Diabetes. 2018;67(12):2601–2614. https://doi.org/10.2337/db18-0155

6. Zhang Z, Hu Y, Xu N, et al. A new way for beta cell neogenesis: transdifferentiation from alpha cells induced by glucagon-like peptide 1. Journal of Diabetes Research. 2019;2019:2583047. https://doi.org/10.1155/2019/2583047

7. Koehler JA, Baggio LL, Lamont BJ, et al. GLP-1 receptor activation modulates pancreatitis-associated gene expression but does not modify susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58(9):2148–2161. https://doi.org/10.2337/db09-0626

8. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes. 2012;61(5):1250–1262. https://doi.org/10.2337/db11-1109

9. Nakamura T, Ito T, Uchida M, et al. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Laboratory Investigation. 2014;94(1):63–78. https://doi.org/10.1038/labinvest.2013.133

10. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes & Endocrinology. 2021;9(10):653–662. https://doi.org/10.1016/S2213-8587(21)00203-5

11. Pinto LC, Falcetta MR, Rados DV, et al. GLP-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Scientific Reports. 2019;9:2375. https://doi.org/10.1038/s41598-019-38956-2

12. Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug Safety Update. 29 January 2026. MHRA Drug Safety Update